ProCE Banner Activity

COSMIC-313: Phase III Study of Nivolumab + Ipilimumab ± Cabozantinib in Previously Untreated IMDC Intermediate- or Poor-Risk Advanced RCC

Slideset Download
Conference Coverage
Results from the phase III COSMIC-313 study showed that PFS was significantly improved with the addition of cabozantinib to nivolumab plus ipilimumab in previously untreated patients with IMDC intermediate- or poor-risk advanced RCC.

Released: September 22, 2022

Expiration: September 21, 2023

No longer available for credit.
Begin Activity


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from


Bristol Myers Squibb

Exelixis, Inc.

Gilead Sciences, Inc.

Merck Sharp & Dohme Corp.